Imatinib Mylan

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Imatinib mesilate 478mg equivalent to imatinib base 400 mg

Disponible desde:

Viatris Limited

Designación común internacional (DCI):

Imatinib mesilate 478 mg (equivalent to imatinib base 400 mg)

Dosis:

400 mg

formulario farmacéutico:

Film coated tablet

Composición:

Active: Imatinib mesilate 478mg equivalent to imatinib base 400 mg Excipient: Colloidal silicon dioxide Crospovidone Hyprolose Hypromellose Iron oxide red Iron oxide yellow Macrogol 400 Magnesium stearate Microcrystalline cellulose Povidone Purified talc Purified water

tipo de receta:

Prescription

Fabricado por:

Pharmaceutical Research Institute (PRI)

indicaciones terapéuticas:

- treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) (for paediatric use see section Dosage and Administration). - treatment of adult and paediatric patients with Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy (for paediatric use see section Dosage and Administration).

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, Alu/PVC/PE/PVDC - 10 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, Alu/PVC/PE/PVDC - 30 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, Alu/PVC/PE/PVDC - 90 tablets - 24 months from date of manufacture stored at or below 25°C

Fecha de autorización:

2016-10-04